Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03212404
Recruitment Status : Recruiting
First Posted : July 11, 2017
Last Update Posted : March 4, 2022
Novotech (Australia) Pty Limited
Information provided by (Responsible Party):
Checkpoint Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Actual Primary Completion Date : November 18, 2021
Estimated Study Completion Date : December 2023